• Explore /
  • Poster
  • / The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Abstract Poster

Authors

null

Daniel John Renouf

Vancouver Cancer Center, Vancouver, BC, Canada

Daniel John Renouf , Neesha C. Dhani , Petr Kavan , Derek J. Jonker , Alice Chia-chi Wei , Tina Hsu , Patricia A. Tang , Barbara Graham , Lisa Gallinaro , Tasnia Hasan , Weiwei Li , Kate Hart , Dongsheng Tu , Christopher J. O'Callaghan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02879318

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 349)

DOI

10.1200/JCO.2018.36.4_suppl.349

Abstract #

349

Poster Bd #

G10

Abstract Disclosures

Similar Posters

First Author: Daniel John Renouf

First Author: Gang Jin

First Author: Julien Taieb

First Author: Eileen Mary O'Reilly